UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis

Annals of the New York Academy of Sciences, 2014-11, Vol.1329 (1), p.33-44

2014

Volltextzugriff (PDF)

Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease

Clinical therapeutics, 2020-06, Vol.42 (6), p.1034-1046

2020

Volltextzugriff (PDF)

Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis

Current medical research and opinion, 2013-12, Vol.29 (12), p.1627-1636

2013

Volltextzugriff (PDF)

Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: A phase I–II, open-label trial

Clinical therapeutics, 2009-10, Vol.31 (10), p.2206-2214

2009

Volltextzugriff (PDF)

Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US

Neuropsychiatric disease and treatment, 2013-01, Vol.9 (default), p.365-370

2013

Volltextzugriff (PDF)

Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-Release 10-mg tablets in patients with multiple sclerosis: A 2-week, open-label, follow-up study

Clinical therapeutics, 2009-10, Vol.31 (10), p.2215-2223

2009

Volltextzugriff (PDF)

Pharmacokinetics of dalfampridine extended release 7.5-mg tablets in healthy subjects and individuals with mild and moderate renal impairment: An open-label study

Journal of clinical pharmacology, 2014-01, Vol.54 (1), p.53-60

2014

Volltextzugriff (PDF)

Assessment of pharmacokinetics and tolerability of intranasal diazepam relative to rectal gel in healthy adults

Epilepsy research, 2014-09, Vol.108 (7), p.1204-1211

2014

Volltextzugriff (PDF)

Dosing feasibility and tolerability of intranasal diazepam in adults with epilepsy

Epilepsia (Copenhagen), 2014-10, Vol.55 (10), p.1544-1550

2014

Volltextzugriff (PDF)

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials

Multiple sclerosis, 2015-09, Vol.21 (10), p.1322-1331

2015

Volltextzugriff (PDF)

Effect of food on the single-dose pharmacokinetics and tolerability of dalfampridine extended-release tablets in healthy volunteers

American journal of health-system pharmacy, 2011-11, Vol.68 (22), p.2148-2154

2011

Volltextzugriff (PDF)

Population pharmacokinetics and pharmacodynamics of dalfampridine-ER in healthy volunteers and in patients with multiple sclerosis

Current medical research and opinion, 2013-12, Vol.29 (12), p.1637-1645

2013

Volltextzugriff (PDF)

Assessment of confirmed urinary tract infection in patients treated with dalfampridine for multiple sclerosis

Postgraduate medicine, 2015-03, Vol.127 (2), p.218-222

2015

Volltextzugriff (PDF)

A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury

Current medical research and opinion, 2008-02, Vol.24 (2), p.425-439

2008

Volltextzugriff (PDF)

Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis

Therapeutics and clinical risk management, 2015-01, Vol.11, p.1-7

2015

Volltextzugriff (PDF)

Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: A single-dose, randomized, open-label, crossover study in healthy subjects

Clinical therapeutics, 2007-04, Vol.29 (4), p.661-669

2007

Volltextzugriff (PDF)

Relative bioavailability of tizanidine hydrochloride capsule formulation compared with capsule contents administered in applesauce: A single-dose, open-label, randomized, two-way, crossover study in fasted healthy adult subjects

Clinical therapeutics, 2008-12, Vol.30 (12), p.2263-2271

2008

Volltextzugriff (PDF)

Pediatric Safety of Tizanidine: Clinical Adverse Event Database and Retrospective Chart Assessment

Paediatric drugs, 2009, Vol.11 (6), p.397-406

2009

Volltextzugriff (PDF)

Dalfampridine Effects Beyond Walking Speed in Multiple Sclerosis

International journal of MS care, 2015-11, Vol.17 (6), p.275-283

2015

Volltextzugriff (PDF)

Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial

International journal of MS care, 2015-05, Vol.17 (3), p.138-145

2015

Volltextzugriff (PDF)

Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers

Clinical therapeutics, 2009-02, Vol.31 (2), p.328-335

2009

Volltextzugriff (PDF)

Effects of food on the single-dose pharmacokinetics/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers

Clinical therapeutics, 2006-09, Vol.28 (9), p.1308-1317

2006

Volltextzugriff (PDF)

Walking impairment in patients with multiple sclerosis - a new therapeutic approach and clinical potential of dalfampridine extended release tablets

Degenerative Neurological and Neuromuscular Disease, 2012-01, Vol.2, p.53-64

2012

Volltextzugriff (PDF)

Dalfampridine in chronic sensorimotor deficits after ischemic stroke: A proof of concept study

Journal of rehabilitation medicine, 2015-11, Vol.47 (10), p.924-931

2015

Volltextzugriff (PDF)

Abstract 150: Dalfampridine in Patients With Chronic Post-Ischemic Stroke Deficits: Results From a Phase 2 Study

Stroke (1970), 2014-02, Vol.45 (suppl_1)

2014

Volltextzugriff (PDF)

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(31)

Sprache

Englisch
(31)

Erscheinungsjahr

n.n

Thema

Humans
(21)
Life Sciences & Biomedicine
(21)
Science & Technology
(21)
Female
(18)
Male
(18)
Middle Aged
(16)
Multiple Sclerosis
(14)
Pharmacokinetics
(14)
Adult
(13)
Aged
(11)
Adolescent
(10)
Pharmacology & Pharmacy
(10)
Biological And Medical Sciences
(9)
Dalfampridine
(9)
Medical Sciences
(9)
Young Adult
(9)
Multiple Sclerosis - Drug Therapy
(8)
Neurology
(8)
Pharmacology. Drug Treatments
(8)
4-Aminopyridine - Administration & Dosage
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis

Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease

Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis

Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: A phase I–II, open-label trial

Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US

Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-Release 10-mg tablets in patients with multiple sclerosis: A 2-week, open-label, follow-up study

Pharmacokinetics of dalfampridine extended release 7.5-mg tablets in healthy subjects and individuals with mild and moderate renal impairment: An open-label study

Assessment of pharmacokinetics and tolerability of intranasal diazepam relative to rectal gel in healthy adults

Dosing feasibility and tolerability of intranasal diazepam in adults with epilepsy

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials

Effect of food on the single-dose pharmacokinetics and tolerability of dalfampridine extended-release tablets in healthy volunteers

Population pharmacokinetics and pharmacodynamics of dalfampridine-ER in healthy volunteers and in patients with multiple sclerosis

Assessment of confirmed urinary tract infection in patients treated with dalfampridine for multiple sclerosis

A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury

Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis

Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: A single-dose, randomized, open-label, crossover study in healthy subjects

Relative bioavailability of tizanidine hydrochloride capsule formulation compared with capsule contents administered in applesauce: A single-dose, open-label, randomized, two-way, crossover study in fasted healthy adult subjects

Pediatric Safety of Tizanidine: Clinical Adverse Event Database and Retrospective Chart Assessment

Dalfampridine Effects Beyond Walking Speed in Multiple Sclerosis

Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial

Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers

Effects of food on the single-dose pharmacokinetics/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers

Walking impairment in patients with multiple sclerosis - a new therapeutic approach and clinical potential of dalfampridine extended release tablets

Dalfampridine in chronic sensorimotor deficits after ischemic stroke: A proof of concept study

Abstract 150: Dalfampridine in Patients With Chronic Post-Ischemic Stroke Deficits: Results From a Phase 2 Study

Suchergebnisse filtern